IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#4813
Positioning
Market Dominance
Wholesale Trade
Wholesale
$14M
Surendra Ajjarapu
SCIENTURE HOLDINGS, Inc is a comprehensive health services and pharmaceutical product company focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs, optimize the prescription journey and patient engagement in the U.S.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
X-AXIS: EV/EBITDA (LOWER = CHEAPER) | Y-AXIS: ROE (HIGHER = ELITE) | RED CIRCLE = SCNX ANALYSIS TARGET
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$ITRN Ituran Location & Control Ltd. | 74 | 95 | 97 | 62 | - | - | 30.4% | 17.5% | 47.8% | 21.2% | 16.8% | 5.1% | 5.1% | 0.0x | $612M | VS | |
$COR Cencora, Inc. | 70 | 84 | 77 | 70 | 21.1x | 11.8x | 123.8% | 2.2% | 3.6% | 0.8% | 0.5% | 9.3% | 0.7% | 508.0x | $60.5B | VS | |
$CENT CENTRAL GARDEN & PET CO | 70 | 84 | 95 | 48 | 5.9x | 3.5x | 10.4% | 4.6% | 31.9% | 8.0% | 5.2% | -2.2% | 0.0% | 75.0x | $2.1B | VS | |
$SNX TD SYNNEX CORP | 67 | 80 | 93 | 57 | 13.5x | 6.2x | 10.0% | 2.6% | 7.0% | 2.3% | 1.3% | 6.9% | 1.2% | 55.0x | $12.4B | VS | |
$HLF HERBALIFE LTD. | 65 | 60 | 75 | 96 | 5.0x | 1.4x | -32.4% | 6.3% | 77.7% | 9.9% | 3.4% | 2.7% | 0.0% | - | $870M | VS | |
$GIC GLOBAL INDUSTRIAL Co | 65 | 82 | 60 | 62 | 18.7x | 12.5x | 24.0% | 12.5% | 35.6% | 7.4% | 5.3% | 3.3% | 2.8% | 0.0x | $1.4B | VS | |
$JXG JX Luxventure Group Inc. | 63 | 84 | 75 | 88 | - | - | 20.4% | 11.9% | 16.8% | 7.8% | 6.2% | 56.5% | 0.0% | 22.0x | $6M | VS | |
$FERG Ferguson Enterprises Inc. /DE/ | 63 | 74 | 48 | 67 | 21.4x | 14.3x | 39.4% | 12.6% | 30.7% | 9.4% | 7.0% | 5.1% | 1.3% | 68.0x | $48.9B | VS | |
$SYY SYSCO CORP | 60 | 68 | 49 | 65 | 22.7x | 9.2x | 89.9% | 5.9% | 18.3% | 3.3% | 1.9% | 3.0% | 2.9% | 595.0x | $35.3B | VS | |
$DXPE DXP ENTERPRISES INC | 60 | 58 | 55 | 79 | 21.6x | 8.5x | 25.1% | 6.2% | 31.4% | 8.5% | 4.2% | 8.6% | 0.0% | 128.0x | $1.9B | VS | |
$SCNX Scienture Holdings, Inc. | 24 | 21 | 10 | 5 | - | - | -20.1% | -15.8% | 51.7% | -178929.4% | -153598.0% | 3055.5% | 0.0% | 2.0x | $14M | ||
| SECTOR BENCH | - | - | - | - | - | 19.1x | 8.2x | 8.6% | 2.7% | 22.5% | 3.3% | 1.4% | 3.3% | 0.3% | 0.5x | - | REF |
Scienture Holdings, Inc. (SCNX) receives a "Avoid" rating with a composite score of 23.5/100. It ranks #4813 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
YOY expansion rate
Core pricing power
Operating efficiency
Bottom-line conversion
Equity capital efficiency
Asset base utilization
Financial leverage load
Direct cash return
Surendra Ajjarapu
Chief Executive Officer
21
33
11
Audit Verdict: Lower quality and stability scores may indicate governance concerns.
No recent insider transactions available for SCNX
Lagging peers — losers tend to keep underperforming
Expensive relative to fundamentals — limited margin of safety
Weak fundamentals — higher risk of value trap
High volatility — wider range of outcomes increases timing risk
Aggressive spending — empire-building risk, dilutive growth
Below-average composite — caution warranted
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Wholesale Trade sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for SCNX.
View All RatingsMaterial decline in asset turnover efficiency detected
High margin volatility — erratic forensic earnings quality
| Factor | Global | Sector | Tilt |
|---|---|---|---|
| PROFITABILITY | 21 | 7 | +14ALPHA |
| MOMENTUM | 5 | 1 | +4NEUTRAL |
| VALUATION | 10 | 3 | +7ALPHA |
| INVESTMENT | 33 | 45 | -12DRAG |
| STABILITY | 11 | 3 | +8ALPHA |
| SHORT INT | 66 | 80 | -14DRAG |
Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.
ROIC -209.5% vs WACC 16.5% (spread -226.0%)
GM 52% vs sector 22%, OM -178929% vs sector 3%
Capital turnover 0.36x, R&D intensity 28.7%
Rev growth 3056%, 10yr history
Interest coverage -2.4x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
Our quantitative model flags Scienture Holdings, Inc. with an Avoid rating, assigning a composite score of 23.5/100 and 1 out of 5 stars. Ranked #4813 of 7,333 stocks, SCNX falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.
Scienture Holdings, Inc. registers a weak quality score of just 21/100, indicating significant profitability challenges. The company reports a return on equity of -20.1% (sector avg: 8.6%), gross margins of 51.7% (sector avg: 22.5%), net margins of -153598.0% (sector avg: 1.4%). Low quality scores are often associated with businesses in turnaround mode, early-stage growth, or structurally challenged industries.
SCNX registers a value score of just 10/100, suggesting the stock trades at a significant premium to its fundamental metrics. Key valuation metrics include a P/B ratio of 0.20x. High-premium valuations like this require strong future execution to avoid multiple compression, and downside risk is elevated if growth disappoints.
Scienture Holdings, Inc.'s investment score of 33/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of 3055.5% vs. a sector average of 3.3% and a return on assets of -15.8% (sector: 2.7%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
Scienture Holdings, Inc. is experiencing notably weak momentum with a score of just 5/100. The stock has underperformed its peers and is trending below major moving averages. Revenue growth stands at 3055.5% year-over-year, while a beta of 1.85 reflects its sensitivity to broader market moves. While deep momentum weakness can occasionally present value opportunities, it often reflects deteriorating fundamentals or structural headwinds that may persist.
Scienture Holdings, Inc. registers a low stability score of 11/100, indicating high volatility and potentially stressed financial conditions. Key stability metrics include a beta of 1.85 and a debt-to-equity ratio of 2.00x (sector avg: 0.5x). Stocks at this level carry elevated capital loss risk and may be unsuitable for conservative portfolios without careful risk management.
SCNX carries a short interest score of 66/100, indicating moderate short selling activity. This is a neutral reading — not enough to signal systemic bearishness, but worth monitoring. Specific risk factors include high market sensitivity (beta: 1.85), micro-cap liquidity risk. At $14M market cap (micro-cap), Scienture Holdings, Inc. offers reasonable institutional liquidity.
Scienture Holdings, Inc. is a micro-cap company in the Wholesale Trade sector, ranked #0 of 50 in its sector (100th percentile) and #4813 of 7,333 overall (34th percentile). Key comparisons include ROE of -20.1% trailing the 8.6% sector median and operating margins of -178929.4% below the 3.3% sector average. This top-quartile standing reflects exceptional competitive strength relative to Wholesale Trade peers.
While SCNX currently exhibits a AVOID profile, superior opportunities exist within the WHOLESALE TRADE sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Wholesale Trade Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Momentum (5) would have the largest impact on the composite score.
ROE 334% BELOW SECTOR MEDIAN
Gross Margin 130% ABOVE SECTOR MEDIAN (FAVORABLE)
Op. Margin 5488732% BELOW SECTOR MEDIAN
AUDIT DATA AS OF SEP 30, 2025 (Q2 FY2025)
We rate Scienture Holdings, Inc. (SCNX) as Avoid with a composite score of 23.5/100 at a current price of $0.39. The stock falls in the bottom quintile of our universe across key quantitative factors, and the multi-factor weakness suggests a high probability of continued underperformance.
The rating is primarily driven by strength in investment (33th percentile) and quality (21th percentile), which together account for the majority of the composite score. Offsetting weakness in momentum (5th percentile) and value (10th percentile) tempers our overall conviction. We assign a No Moat rating (33/100), Very High uncertainty, and Poor capital allocation.
Key items to watch: momentum to confirm whether the current price trend has legs; sustainability of the current growth rate; the path to profitability. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is narrowing, which raises the risk of a future downgrade if the trend persists.
Scienture Holdings, Inc. holds a top-quartile position (#0 of 50) within the Wholesale Trade sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 23.5/100 places it at rank #4813 in our full 7,333-stock universe. At $14M in market capitalization, Scienture Holdings, Inc. is a small-cap player in the Wholesale Trade space, which limits certain scale advantages but may allow for more agile strategic execution.
Revenue is growing at 3056%, though momentum at the 5th percentile suggests the market has not yet fully recognized this trajectory. This potential disconnect between fundamental improvement and market recognition could represent an opportunity for patient investors if the growth trend persists.
The margin cascade tells an important story: gross margins of 52% (+29.2pp vs sector) narrow to operating margins of -178929% (-178932.7pp vs sector) and net margins of -153598.0%, yielding a gross-to-net conversion rate of -297152%. The significant margin erosion from gross to net suggests elevated operating expenses, high interest costs, or other structural drags that warrant monitoring.
At a current price of $0.39, Scienture Holdings, Inc. is trading at a premium to fundamental value. Our value factor score of 10/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. The premium valuation implies the market is pricing in significant future growth or quality improvements that are not yet fully reflected in current fundamentals.
The stock currently trades at P/B of 0.2x, P/S of 24.8x. We evaluate these multiples in the context of both absolute levels and sector-relative positioning to form our valuation view.
Gross margins of 52% signal strong pricing power and brand/IP advantages — businesses with margins above 40% have historically demonstrated more resilient earnings through economic cycles.
Revenue growth of 3056% confirms the business is expanding its addressable market — growth at this level typically supports multiple expansion and attracts institutional capital.
A conservative balance sheet (2% D/E) provides financial flexibility for acquisitions, buybacks, or weathering economic downturns without dilution.
The Avoid rating (composite 23.5/100) reflects multi-factor weakness, and historically, stocks in this scoring range have underperformed the market by a meaningful margin.
Thin net margins of -153598.0% provide limited cushion against cost pressures, competitive pricing, or macroeconomic headwinds — even small changes in costs could swing the company to a loss.
We assign a Very High uncertainty rating to Scienture Holdings, Inc.. The stock exhibits multiple compounding risk factors: elevated market sensitivity (beta of 1.85), current negative profitability (net margin -153598.0%), below-average price stability (11th percentile). The extreme uncertainty around future cash flows makes precise valuation difficult, and the range of outcomes is exceptionally wide. Only investors with high risk tolerance and extended time horizons should consider this name.
Specific risk factors that inform our assessment include: elevated market sensitivity (beta of 1.85); current negative profitability (net margin -153598.0%); below-average price stability (11th percentile); weak quality scores (21th percentile). Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 11th percentile and quality factor at the 21th percentile provide a quantitative summary of the overall risk landscape.
Key risk mitigants include: healthy gross margins of 52% provide a buffer against cost pressures; conservative leverage (2% D/E) limits balance sheet risk. These factors partially offset the identified risks and provide downside protection in adverse scenarios. On balance, the risk-reward profile warrants caution and disciplined position management.
We rate Scienture Holdings, Inc.'s capital allocation as Poor. Key concerns include low returns on equity (-20.1%), negative profitability, weak asset returns (ROA -15.8%). Exemplary capital allocators generate ROE above 20% and maintain conservative leverage — Scienture Holdings, Inc. significantly underperforms these benchmarks, raising questions about management's ability to create shareholder value.
Investors should scrutinize management's reinvestment decisions and balance sheet trajectory before committing capital. Poor capital allocation often compounds over time: overlevered balance sheets limit strategic flexibility, while low returns on capital destroy shareholder value. We would need to see sustained improvement in profitability metrics and balance sheet discipline before considering an upgrade.
In summary, Scienture Holdings, Inc. receives a Avoid rating with a composite score of 23.5/100 (rank #4813 of 7,333). Our quantitative framework assigns a No Moat (33/100, trend: narrowing), Very High uncertainty, and Poor capital allocation. The average factor score across quality, value, momentum, stability, and investment is 16/100.
Our analysis does not support a constructive view on Scienture Holdings, Inc. at this time. The combination of limited competitive advantages, very high uncertainty, and poor capital allocation suggests unfavorable risk-reward at current levels. We recommend investors avoid new positions and existing holders consider reducing exposure.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We do not assign Scienture Holdings, Inc. a meaningful economic moat, scoring 33/100 on our composite assessment. The ROIC-WACC spread of -226.0% is the primary signal of economic value creation. Current fundamentals do not demonstrate the kind of durable competitive advantages — such as superior returns on invested capital, margin superiority, or reinvestment efficiency — that would protect the company from competitive erosion over the long term. The highest-scoring pillar, growth durability, reached only 10.2/20.
The strongest moat sources are growth durability (10.2/20) and financial resilience (8/20). Rev growth 3056%, 10yr history. Interest coverage -2.4x. These pillars form the core of Scienture Holdings, Inc.'s competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include economic value creation (0/20) and reinvestment efficiency (7/20). ROIC -209.5% vs WACC 16.5% (spread -226.0%). Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Narrowing. ROIC has declined at ~307.3pp per year, and operating margins show fundamental deterioration. Investors should monitor these indicators closely — a sustained narrowing trend often precedes material downgrades in our moat assessment.
Key profit drivers include gross margins of 52% providing a solid profitability foundation, robust top-line growth of 3056% expanding the revenue base. The margin cascade from 52% gross to -178929% operating to -153598.0% net reveals the company's cost structure and reinvestment intensity. Our analysis indicates that profit quality raises some durability concerns, with the quality factor at the 21th percentile.
The margin profile shows gross margins of 52%, operating margins of -178929%, net margins of -153598.0%. Return metrics include ROE of -20.1% and ROA of -15.8%. Relative to the Wholesale Trade sector, gross margins are 29.2 percentage points above the sector median of 22%, and ROE of -20.1% compares to a sector median of 8.6%.
The balance sheet reflects a conservatively managed balance sheet with D/E of 2%, revenue growth of 3056%. The sector median D/E is 1%, putting Scienture Holdings, Inc. at higher leverage than the typical peer. Overall balance sheet health is adequate for the current business environment.
Weak momentum (5th percentile) suggests institutional selling pressure and unfavorable technical dynamics that may persist.
Below-average quality (21th percentile) raises durability concerns about the fundamental profile and increases the risk of negative earnings surprises.
High beta of 1.85 means amplified losses in market selloffs — in a broad market correction, this stock would likely decline more than the index.
Above 50MA
37.18%
Net New Highs
+51081
Company highlights accelerating access and revenue growth for ARBLI™ and confirms REZENOPY™ launch timeline, addressing a combined US annual losartan and naloxone market size of close to $385 million Outlines Q1 2026 outlook and reports significant balance sheet improvement last quarter COMMACK, NY, Feb. 03, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patient
U.S. Naloxone Market: ~$154 million in annual sales and 9.3 million units annually COMMACK, NY, Jan. 14, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today announced that the United States Patent and Trad
U.S. Naloxone Market: ~$154 million in annual sales and 9.3 million units annually COMMACK, NY, Dec. 22, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today provided an update on the commercial launch of R